Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Gild | Vintage Vibes

How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks

Gilead Sciences has outperformed other healthcare stocks, and analysts remain highly optimistic about the stock’s outlook

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Gilead Sciences's Q1 2026 Earnings: What to Expect

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

3 Top-Rated Stocks to Buy to Hedge Against Stagflation as Middle East Conflict Drags On

Amid widespread uncertainties, these three names can shield your portfolio.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Blue-Chip Stocks Built for a Rotating Market

3 Blue-Chip Stocks Built for a Rotating Market

Investors are rotating out of overvalued mega-cap tech as the broader economy heats up; these three blue-chip stocks are attracting attention

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

Stock Index Futures Muted With U.S. Retail Sales Data in Focus

Stock Index Futures Muted With U.S. Retail Sales Data in Focus

March S&P 500 E-Mini futures (ESH26) are up +0.03%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.04% this morning, taking a breather after a recent rally as investors await a slew of U.S. economic data, with particular attention on the retail sales report, remarks from Federal Reserve officials,…

This Overlooked Biotech Giant Could Surprise Investors This Quarter

This Overlooked Biotech Giant Could Surprise Investors This Quarter

Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.

Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?

Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?

Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Gilead Sciences Earnings Preview: What to Expect

Gilead Sciences Earnings Preview: What to Expect

Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.

Get all your
news in one place.

100's of premium titles.
One news app.

3 Cash-Flow Machines Investors May Want Heading Into 2026

A company's cash flow can reveal its day-to-day success and sustainability, and these three firms are all thriving when it comes to cash generation.

3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains

GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

3 Cash-Rich Stocks With High Growth Potential Right Now

Discover three high free cash flow yield stocks—Salesforce, Applied Materials, and Gilead Sciences—offering stability and long-term growth potential

Get all your
news in one place.

100's of premium titles.
One news app.

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

What to Expect From Gilead Sciences' Next Quarterly Earnings Report

Gilead Sciences will release its third-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy.

Biotech Sector May Flip to Market Leader by Year-End

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Corporate Earnings

Places

397,743 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play